VISTA: A Promising Target for Cancer Immunotherapy?

References

• He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30(8):660–669. doi:10.1038/s41422-020-0343-4
   PubMed Web of Science ®Google Scholar
• Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1–11. doi:10.1038/s12276-018-0191-1
   PubMed Web of Science ®Google Scholar
• Xu W, Hiếu T, Malarkannan S, Wang L. The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cell Mol Immunol. 2018;15(5):438–446. doi:10.1038/cmi.2017.148
   Web of Science ®Google Scholar
• De Sousa Linhares A, Leitner J, Grabmeier-Pfistershammer K, Steinberger P. Not all immune checkpoints are created equal. Front Immunol. 2018;9:1909. doi:10.3389/fimmu.2018.01909
   PubMed Web of Science ®Google Scholar
• Torphy R, Schulick R, Zhu Y. Newly emerging immune checkpoints: promises for future cancer therapy. Int J Mol Sci. 2017;18(12):2642. doi:10.3390/ijms18122642
   PubMed Web of Science ®Google Scholar
• Lambertini M, Preusser M, Zielinski CC. New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: introducing an “ESMO open – cancer horizons” series. ESMO Open. 2019;4(Suppl3):e000501. doi:10.1136/esmoopen-2019-000501
   Web of Science ®Google Scholar
• Rossi G, Russo A, Tagliamento M, et al. Precision medicine for NSCLC in the era of immunotherapy: new biomarkers to select the most suitable treatment or the most suitable patient. Cancers. 2020;12(5):1125. doi:10.3390/cancers12051125
   PubMed Web of Science ®Google Scholar
• Rebuzzi SE, Zullo L, Rossi G, et al. Novel emerging molecular targets in non-small cell lung cancer. Int J Mol Sci. 2021;22(5):2625. doi:10.3390/ijms22052625
   PubMed Web of Science ®Google Scholar
• Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA. Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor. Semin Immunol. 2019;42:101305. doi:10.1016/j.smim.2019.101305
   PubMed Web of Science ®Google Scholar
• Solinas C, Aiello M, Rozali E, Lambertini M, Willard-Gallo K, Migliori E. Programmed cell death-ligand 2: a neglected but important target in the immune response to cancer? Transl Oncol. 2020;13(10):100811. doi:10.1016/j.tranon.2020.100811
   Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Friedlaender A, Addeo A, Banna G. New emerging targets in cancer immunotherapy: the role of TIM3. ESMO Open. 2019;4:e000497. doi:10.1136/esmoopen-2019-000497
   PubMed Web of Science ®Google Scholar
• Acharya N, Sabatos-Peyton C, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer. 2020;8(1):e000911. doi:10.1136/jitc-2020-000911
   PubMed Web of Science ®Google Scholar
• Chauvin J-M, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8(2):e000957. doi:10.1136/jitc-2020-000957
   PubMed Web of Science ®Google Scholar
• Yang S, Wei W, Zhao Q. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Int J Biol Sci. 2020;16(11):1767–1773. doi:10.7150/ijbs.41105
   PubMed Web of Science ®Google Scholar
• Genova C, Boccardo S, Mora M, et al. Correlation between B7-H4 and survival of non-small-cell lung cancer patients treated with nivolumab. J Clin Med. 2019;8(10):1566. doi:10.3390/jcm8101566
   Web of Science ®Google Scholar
• Tagliamento M, Bironzo P, Novello S. New emerging targets in cancer immunotherapy: the role of VISTA. ESMO Open. 2019;4:e000683. doi:10.1136/esmoopen-2020-000683
   Google Scholar
• De Mattos-arruda L, Blanco-Heredia J, Aguilar-Gurrieri C, Carrillo J, Blanco J. New emerging targets in cancer immunotherapy: the role of neoantigens. ESMO Open. 2019;4:e000684. doi:10.1136/esmoopen-2020-000684
   Web of Science ®Google Scholar
• ElTanbouly MA, Schaafsma E, Noelle RJ, Lines JL. VISTA: coming of age as a multi‐lineage immune checkpoint. Clin Exp Immunol. 2020;200(2):120–130. doi:10.1111/cei.13415
   Web of Science ®Google Scholar
• Huang X, Zhang X, Li E, et al. VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. J Hematol Oncol. 2020;13(1):83. doi:10.1186/s13045-020-00917-y
   PubMed Web of Science ®Google Scholar
• Wang L, Rubinstein R, Lines JL, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med. 2011;208(3):577–592. doi:10.1084/jem.20100619
   PubMed Web of Science ®Google Scholar
• Aloia L, Parisi S, Fusco L, Pastore L, Russo T. Differentiation of embryonic stem cells 1 (Dies1) is a component of Bone Morphogenetic Protein 4 (BMP4) signaling pathway required for proper differentiation of mouse embryonic stem cells. J Biol Chem. 2010;285(10):7776–7783. doi:10.1074/jbc.M109.077156
   Web of Science ®Google Scholar
• Battista M, Musto A, Navarra A, Minopoli G, Russo T, Parisi S. miR-125b regulates the early steps of ESC differentiation through dies1 in a TGF-independent manner. Int J Mol Sci. 2013;14(7):13482–13496. doi:10.3390/ijms140713482
   Web of Science ®Google Scholar
• Flies DB, Wang S, Xu H, Chen L. Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol. 2011;187(4):1537–1541. doi:10.4049/jimmunol.1100660
   Web of Science ®Google Scholar
• Lines JL, Pantazi E, Mak J, et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 2014;74(7):1924–1932. doi:10.1158/0008-5472.CAN-13-1504
   PubMed Web of Science ®Google Scholar
• Bharaj P, Chahar HS, Alozie OK, et al. Characterization of Programmed Death-1 Homologue-1 (PD-1H) expression and function in normal and HIV infected individuals. Kaveri SV, ed. PLoS One. 2014;9(10):e109103. doi:10.1371/journal.pone.0109103
   Web of Science ®Google Scholar
• Wang L, Le Mercier I, Putra J, et al. Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. Proc Natl Acad Sci. 2014;111(41):14846–14851. doi:10.1073/pnas.1407447111
   PubMed Web of Science ®Google Scholar
• Flies DB, Han X, Higuchi T, et al. Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell-mediated immunity. J Clin Invest. 2014;124(5):1966–1975. doi:10.1172/JCI74589
   PubMed Web of Science ®Google Scholar
• Flies DB, Higuchi T, Chen L. Mechanistic assessment of PD-1H coinhibitory receptor–induced T cell tolerance to allogeneic antigens. J Immunol. 2015;194(11):5294–5304. doi:10.4049/jimmunol.1402648
   Web of Science ®Google Scholar
• Liu J, Yuan Y, Chen W, et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci. 2015;112(21):6682LP- 6687. doi:10.1073/pnas.1420370112
   Web of Science ®Google Scholar
• Tham EL, Freeley SJ, Bearder S, et al. VISTA deficiency protects from immune complex-mediated glomerulonephritis by inhibiting neutrophil activation. J Autoimmun. 2020;113:102501. doi:10.1016/j.jaut.2020.102501
   Web of Science ®Google Scholar
• Hid Cadena R, Reitsema RD, Huitema MG, et al. Decreased expression of negative immune checkpoint VISTA by CD4+ T cells facilitates T helper 1, T helper 17, and T follicular helper lineage differentiation in GCA. Front Immunol. 2019;10:1638. doi:10.3389/fimmu.2019.01638
   PubMed Web of Science ®Google Scholar
• Borggrewe M, Grit C, Den dunnen WFA, et al. VISTA expression by microglia decreases during inflammation and is differentially regulated in CNS diseases. Glia. 2018;66(12):2645–2658. doi:10.1002/glia.23517
   Web of Science ®Google Scholar
• ElTanbouly MA, Schaafsma E, Smits NC, et al. VISTA re-programs macrophage biology through the combined regulation of tolerance and anti-inflammatory pathways. Front Immunol. 2020;11:580187. doi:10.3389/fimmu.2020.580187
   Web of Science ®Google Scholar
• Wang J, Wu G, Manick B, et al. VSIG-3 as a ligand of VISTA inhibits human T-cell function. Immunology. 2019;156(1):74–85. doi:10.1111/imm.13001
   Web of Science ®Google Scholar
• Buchbinder EI. Immune checkpoint therapies for melanoma. Hematol Oncol Clin North Am. 2021;35(1):99–109. doi:10.1016/j.hoc.2020.08.013
   Web of Science ®Google Scholar
• Rosenbaum SR, Knecht M, Mollaee M, et al. FOXD3 regulates VISTA expression in melanoma. Cell Rep. 2020;30(2):510–524.e6. doi:10.1016/j.celrep.2019.12.036
   Web of Science ®Google Scholar
• Xu W, Dong J, Zheng Y, et al. Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell–mediated inflammation and immunosuppression. Cancer Immunol Res. 2019;7(9):1497LP- 1510. doi:10.1158/2326-6066.CIR-18-0489
   Web of Science ®Google Scholar
• Kakavand H, Jackett LA, Menzies AM, et al. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Mod Pathol off J U S Can Acad Pathol Inc. 2017;30(12):1666–1676. doi:10.1038/modpathol.2017.89
   PubMed Web of Science ®Google Scholar
• Kuklinski LF, Yan S, Li Z, et al. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival. Cancer Immunol Immunother. 2018;67(7):1113–1121. doi:10.1007/s00262-018-2169-1
   PubMed Web of Science ®Google Scholar
• Villarroel-Espindola F, Yu X, Datar I, et al. Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer. Clin Cancer Res. 2018;24(7):1562–1573. doi:10.1158/1078-0432.CCR-17-2542
   PubMed Web of Science ®Google Scholar
• Brcic L, Stanzer S, Krenbek D, et al. Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung. Virchows Arch. 2018;472(4):589–598. doi:10.1007/s00428-018-2326-0
   PubMed Web of Science ®Google Scholar
• Ladanyi M, Robinson BW, Campbell PJ; for the TCGA Research Network. The TCGA malignant pleural mesothelioma (MPM) project: VISTA expression and delineation of a novel clinical-molecular subtype of MPM. J Clin Oncol. 2018;36(15_suppl):8516. doi:10.1200/JCO.2018.36.15_suppl.8516
   Web of Science ®Google Scholar
• Muller S, Victoria Lai W, Adusumilli PS, et al. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. Mod Pathol. 2020;33(2):303–311. doi:10.1038/s41379-019-0364-z
   PubMed Web of Science ®Google Scholar
• Rooney C, Nixon C, Blyth K, Sethi T, Murphy D, McCaughan F. S45 VISTA expression in malignant pleural mesothelioma. Novel Insights into Malignant Pleural Disease. Thorax. 2019:74:A29.2–A30. doi:10.1136/thorax-2019-BTSabstracts2019.51
   Google Scholar
• Liu J, Xie X, Xuan C, et al. High-density infiltration of V-domain immunoglobulin suppressor of T-cell activation up-regulated immune cells in human pancreatic cancer. Pancreas. 2018;47(6):725–731. doi:10.1097/mpa.0000000000001059
   Web of Science ®Google Scholar
• Byers JT, Paniccia A, Kaplan J, et al. Expression of the novel costimulatory molecule B7-H5 in pancreatic cancer. Ann Surg Oncol. 2015;22(3):1574–1579. doi:10.1245/s10434-014-4293-2
   Web of Science ®Google Scholar
• Blando J, Sharma A, Higa MG, et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019;116(5):1692–1697. doi:10.1073/pnas.1811067116
   PubMed Web of Science ®Google Scholar
• Xie S, Huang J, Qiao Q, et al. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. Cancer Immunol Immunother. 2018;67(11):1685–1694. doi:10.1007/s00262-018-2227-8
   PubMed Web of Science ®Google Scholar
• Zaravinos A, Roufas C, Nagara M, et al. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. J Exp Clin Cancer Res. 2019;38(1):364. doi:10.1186/s13046-019-1372-z
   Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421. doi:10.1038/nature12477
   PubMed Web of Science ®Google Scholar
• Xie X, Zhang J, Shi Z, et al. The expression pattern and clinical significance of the immune checkpoint regulator VISTA in human breast cancer. Front Immunol. 2020;11:2808. doi:10.3389/fimmu.2020.563044
   Web of Science ®Google Scholar
• Zong L, Mo S, Yu S, et al. Expression of the immune checkpoint VISTA in breast cancer. Cancer Immunol Immunother. 2020;69(8):1437–1446. doi:10.1007/s00262-020-02554-3
   Web of Science ®Google Scholar
• Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2016;2(10):1354–1360. doi:10.1001/jamaoncol.2016.1061
   PubMed Web of Science ®Google Scholar
• Solinas C, Carbognin L, De Silva P, Criscitiello C, Lambertini M. Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: current state of the art. Breast. 2017;35:142–150. doi:10.1016/j.breast.2017.07.005
   PubMed Web of Science ®Google Scholar
• Losurdo A, De Sanctis R, Fernandes B, et al. Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practice. Sci Rep. 2020;10(1):20100. doi:10.1038/s41598-020-77043-9
   PubMed Web of Science ®Google Scholar
• Agostinetto E, Eiger D, Punie K, de Azambuja E. Emerging therapeutics for patients with triple-negative breast cancer. Curr Oncol Rep. 2021;23(5):57. doi:10.1007/s11912-021-01038-6
   PubMed Web of Science ®Google Scholar
• Cao X, Ren X, Zhou Y, et al. VISTA expression on immune cells correlates with favorable prognosis in patients with triple-negative breast cancer. Front Oncol. 2021;10:3010. doi:10.3389/fonc.2020.583966
   Web of Science ®Google Scholar
• Pilones KA, Hensler M, Daviaud C, et al. Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade. OncoImmunology. 2020;9(1):1830524. doi:10.1080/2162402X.2020.1830524
   PubMed Web of Science ®Google Scholar
• Hong S, Yuan Q, Xia H, et al. Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy. Protein Cell. 2019;10(11):840–845. doi:10.1007/s13238-019-0642-z
   PubMed Web of Science ®Google Scholar
• Ni L, Dong C. New checkpoints in cancer immunotherapy. Immunol Rev. 2017;276(1):52–65. doi:10.1111/imr.12524
   Web of Science ®Google Scholar
• Zong L, Zhou Y, Zhang M, Chen J, Xiang Y. VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer. Cancer Immunol Immunother. 2020;69(1):33–42. doi:10.1007/s00262-019-02434-5
   Web of Science ®Google Scholar
• Mulati K, Hamanishi J, Matsumura N, et al. VISTA expressed in tumour cells regulates T cell function. Br J Cancer. 2019;120(1):115–127. doi:10.1038/s41416-018-0313-5
   PubMed Web of Science ®Google Scholar
• Kim TK, Han X, Wang J, et al. PD-1H (VISTA) induces immune evasion in acute myeloid leukemia. Blood. 2017;130(Supplement1):2658. doi:10.1182/blood.V130.Suppl_1.2658.2658
   Google Scholar
• Wang L, Jia B, Claxton DF, et al. VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML. Oncoimmunology. 2018;7(9):e1469594. doi:10.1080/2162402X.2018.1469594
   PubMed Web of Science ®Google Scholar
• Musielak B, Kocik J, Skalniak L, et al. CA-170 – a potent small-molecule PD-L1 inhibitor or not? Molecules. 2019;24(15):2804. doi:10.3390/molecules24152804
   PubMed Web of Science ®Google Scholar
• Deng J, Le Mercier I, Kuta A, Noelle RJ, New A. VISTA on combination therapy for negative checkpoint regulator blockade. J Immunother Cancer. 2016;4(1):86. doi:10.1186/s40425-016-0190-5
   Web of Science ®Google Scholar
• Lee JJ, Powderly JD, Patel MR, et al. Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas. J Clin Oncol. 2017;35(15_suppl):TPS3099–TPS3099. doi:10.1200/JCO.2017.35.15_suppl.TPS3099
   Web of Science ®Google Scholar
• Powderly J, Patel MR, Lee JJ, et al. CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in phase 1 study. Ann Oncol. 2017;28:v405–v406. doi:10.1093/annonc/mdx376.007
   Web of Science ®Google Scholar
• Bang Y-L, Sosman JA, Daud A, et al. Phase 1 study of CA-170, a first-in-class, orally available, small molecule immune checkpoint inhibitor (ICI) dually targeting VISTA and PD-L1, in patients with advanced solid tumors or lymphomas. in P341. (2018) 6:175. J Immunother Cancer. 2018;6(S1):114, s40425-018-0422-y. doi:10.1186/s40425-018-0422-y
   Web of Science ®Google Scholar
• Zauderer M, Brody J, Marron T, et al. P2.06-07 phase 1 study of CA-170: first-in-class small molecule targeting VISTA/PD-L1 in patients with malignant pleural mesothelioma. J Thorac Oncol. 2019;14(10):S757–S758. doi:10.1016/j.jtho.2019.08.1625
   Web of Science ®Google Scholar
• Zauderer M, Brody J, Marron T, et al. First-in-class small molecule CA-170 targeting VISTA: a report on efficacy outcomes from a cohort of 12 malignant pleural mesothelioma (MPM) patients in study CA- 170–101. J Immunother Cancer 2019;7:O28. J Immunother Cancer. 2019;7(S1):283, s40425-019-0764-0. doi:10.1186/s40425-019-0764-0
   Google Scholar
• Radhakrishnan VS, Bakhshi S, Prabhash K, et al. Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients (pts) with advanced solid tumor and Hodgkin lymphoma. J Immunother Cancer 2018;6:P714. J Immunother Cancer. 2018;6(S2):1–13. doi:10.1186/s40425-018-0434-7
   Web of Science ®Google Scholar
• He X-L, Zhou Y, Lu H-Z, Li Q-X, Wang Z. Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis. Sci Rep. 2020;10(1):2662. doi:10.1038/s41598-020-59608-w
   Web of Science ®Google Scholar
• Gabrielson A, Wu Y, Wang H, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res. 2016;4(5):419–430. doi:10.1158/2326-6066.CIR-15-0110
   PubMed Web of Science ®Google Scholar
• Liang Y, Lü W, Zhang X, Lü B. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer. Diagn Pathol. 2018;13(1):93. doi:10.1186/s13000-018-0770-4
   PubMed Web of Science ®Google Scholar
• Li J, Wang J, Chen R, Bai Y, Lu X. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Oncotarget. 2017;8(9):15621–15631. doi:10.18632/oncotarget.14919
   PubMedGoogle Scholar
• Goode EL, Block MS, Kalli KR, et al.; Ovarian Tumor Tissue Analysis (OTTA) Consortium. Dose-response association of CD8 +tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol. 2017;3(12):e173290. doi:10.1001/jamaoncol.2017.3290
   PubMed Web of Science ®Google Scholar
• Nguyen N, Bellile E, Thomas D, et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2016;38(7):1074–1084. doi:10.1002/hed.24406
   PubMed Web of Science ®Google Scholar
• Ye S-L, Li X-Y, Zhao K, Feng T. High expression of CD8 predicts favorable prognosis in patients with lung adenocarcinoma: a cohort study. Medicine. 2017;96(15):e6472. doi:10.1097/MD.0000000000006472
   Web of Science ®Google Scholar
• Chung YS, Kim M, Cha YJ, Kim KA, Shim HS. Expression of V-set immunoregulatory receptor in malignant mesothelioma. Mod Pathol. 2020;33(2):263–270. doi:10.1038/s41379-019-0328-3
   PubMed Web of Science ®Google Scholar